AID  Vol.12 No.2 , June 2022
Serological Investigation of COVID-19 Antibodies in Armenia
Show more
Abstract: Background: In December 2019 in Wuhan China the new coronavirus outbreak emerged and quickly spread in all parts of the world resulting to more than 500,000,000 infection cases and around 6,200,000 deaths. The global incidence of the infection is still growing as well as number of deaths. COVID-19 is a new virus, therefore not much is known about the immune response of infected organism, which is crucial not only for vaccination policy development, but also for identification of public health strategies. Aim: Current research aims to describe COVID-19 IgG levels depending on symptoms, antibiotic and antiviral medications intake history, existing chronic condition and smoking status during March-December of 2020 in Armenia. Furthermore, the study aims to help elucidate the fraction of asymptomatic or presymptomatic/sub- clinical infections in the population and understand the main risk factors for infection complication. Methodology: The cross-sectional study with convenience sampling of individuals who turned to “EcoSense” laboratories to be tested for COVID-19 IgG were examined. The NovaTec SARS-CoC-2 (COVID-19) IgG COVG940 96 Determinations ELISA test kits were used. The questionnaire was filled regarding the COVID-19 status, symptoms, exposure history, disease history, pre-existing chronic conditions, medication and vaccination history. The descriptive as well as multivariate analysis was performed. Results: Overall 1573 testing was performed 837 of subjects agreed to participate in the interview. 24.1% of participants had laboratory confirmed COVID-19 but by the time of interview were already recovered. 212 (25.3%) participants had positive IgG levels, among 126 (15.1%) participants IgG levels were in the grey zone. Out of PCR confirmed cases only 58.7% had positive IgG levels and 3.9% IgG level was in the grey zone. Headache was the most common symptom among participants (37.2% among all participants and 53.1% among participants who previously had positive COVID-19 PCR test). The second most common symptom was anosmia (23.7% among all participants and 48.9% among participants who previously had positive COVID-19 PCR test). 5.4% of participants mentioned previous hospitalization due to COVID-19, 71 (8.5%) mentioned being diagnosed with pneumonia and 24 (2.9%) participants mentioned being admitted to ICU, 20 (2.4%) mentioned receiving oxygen therapy and 4 (0.5%) of the participants mentioned receiving an artificial ventilation of lungs. There was a weak correlation between symptom sum score and IgG titers. The Correlation coefficient was 0.273, p < 0.05, R2 = 0.075. The linear regression analysis was also performed. The obtained results indicate that the number of symptoms patients have is a significant predictor for IgG level F(1, 711) = 57.45, P < 0.01, R2 = 0.075. Conclusions: Our study reviled that around half of PCR confirmed COVID-19 patients do not have positive titer for IgG, most importantly the number of symptoms is a weak predictor for IgG levels, which contradicts the existing misassumption regarding severity of clinical manifestation of COVID-19 and post-infection immunity.
Cite this paper: Nazaryan, I. , Mnatsakanyan, S. and Pepanyan, N. (2022) Serological Investigation of COVID-19 Antibodies in Armenia. Advances in Infectious Diseases, 12, 337-346. doi: 10.4236/aid.2022.122027.

[1]   Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J. and Prescott, H.C. (2020) Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). JAMA, 324, 782-793.

[2]   Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020) China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine, 382, 727-733.

[3]   Dong, E., Du, H. and Gardner, L. (2020) An Interactive Web-Based Dashboard to Track COVID-19 in Real Time. The Lancet Infectious Diseases, 20, 533-534.

[4]   Nasserie, T., Hittle, M. and Goodman, S.N. (2021) Assessment of the Frequency and Variety of Persistent Symptoms among Patients with COVID-19: A Systematic Review. JAMA Network Open, 4, Article ID: e2111417.

[5]   Yong, S.E.F., Anderson, D.E., Wei, W.E., Pang, J., Chia, W.N., Tan, C.W., et al. (2020) Connecting Clusters of COVID-19: An Epidemiological and Serological Investigation. The Lancet Infectious Diseases, 20, 809-815.

[6]   Grenache, D.G., Sever, C., Mathur, G. and Mathur, S. (2020) Antibody Testing For COVID-19. American Journal of Clinical Pathology, 154, 425-426.

[7]   Tang, Y.W., Schmitz, J.E., Persing, D.H. and Stratton, C.W. (2020) Laboratory Diagnosis of COVID-19: Current Issues and Challenges. Journal of Clinical Microbiology, 58, Article ID: e00512-20.

[8]   Alimohamadi, Y., Sepandi, M., Taghdir, M. and Hosamirudsari, H. (2020) Determine the Most Common Clinical Symptoms in COVID-19 Patients: A Systematic Review and Meta-Analysis. Journal of Preventive Medicine and Hygiene, 61, E304-E312.


[10]   Alfegob, D., Sullivana, A., Poiriera, B., Williamsa, J., Grovera, A., Gillima, L., Adcocka, D. and Letovskya, S. (2021) A Population-Based Analysis of the Longevity of SARS-CoV-2 Antibody Seropositivity in the United States. eClinicalMedicine, 36, Article ID: 100902.

[11]   Ibarrondo, F.J., Fulcher, J.A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M.A., et al. (2020) Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19. The New England Journal of Medicine, 383, 1085-1087.

[12]   Berlin, I. and Thomas, D. (2020) Does Smoking Protect against Being Hospitalized For COVID-19? International Journal of Environmental Research and Public Health, 17, Article No. 9559.

[13]   González-Rubio, J., Navarro-López, C., López-Nájera, E., López-Nájera, A., Jiménez-Díaz, L., Navarro-López, J.D., et al. (2020) A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19. International Journal of Environmental Research and Public Health, 17, Article No. 7394.

[14]   Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., et al. (2021) COVID-19 Antibody Seroprevalence in Santa Clara County, California. International Journal of Epidemiology, 50, 410-419.

[15]   Peeling, R.W. (2020) Serology Testing in the COVID-19 Pandemic Response. The Lancet Infectious Diseases, 20, E245-E249.

[16]   Hou, H., Wang, T., Zhang, B., Luo, Y., Mao, L., Wang, F., et al. (2020) Detection of IgM and IgG Antibodies in Patients with Coronavirus Disease 2019. Clinical & Translational Immunology, 9, Article ID: e01136.

[17]   Long, Q., Liu, B., Deng, H., Wu, G.C., Deng, K., Chen, Y.K., et al. (2020) Antibody Responses to SARS-CoV-2 in Patients with COVID-19. Nature Medicine, 26, 845-848.

[18]   Sun, B., Feng, Y., Mo, X., Zheng, P., Wang, Q., Li, P., et al. (2020) Kinetics of SARS-CoV-2 Specific IgM and IgG Responses in COVID-19 Patients. Emerging, Microbes & Infections, 9, 940-948.

[19]   Seeßle, J., Waterboer, T., Hippchen, T., Simon, J., Kirchner, M., Lim, A., et al. (2022) Persistent Symptoms in Adult Patients 1 Year after Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clinical Infectious Diseases, 74, 1191-1198.

[20]   Amin, M.T., Hasan, M. and Bhuiya, N.M.M.A. (2021) Prevalence of COVID-19 Associated Symptoms, Their Onset and Duration, and Variations among Different Groups of Patients in Bangladesh. Front Public Health, 9, Article ID: 738352.

[21]   Esakandari, H., Nabi-Afjadi, M., Fakkari-Afjadi, J., Farahmandian, N., Miresmaeili, S.M. and Bahreini, E. (2020) A Comprehensive Review of COVID-19 Characteristics. Biological Procedures Online, 22, Article No. 19.